Tenax Therapeutics (TENX) Stock Forecast & Price Target

Tenax Therapeutics is viewed positively because its phase three focus on levosimendan targets pulmonary hypertension, a setting with high unmet need where even modest signals could matter clinically. Despite the uncertainty around the 6MWT result, the subgroup benefit in patients below the median baseline 6MWT, the -49% NT-proBNP reduction versus placebo, and the company’s planned Type C meeting suggest there may still be a viable path forward in sicker patients. The outlook also reflects disciplined valuation assumptions, including a DCF using an 11% WACC, lower probability of success, and reduced TAM and penetration, while the updated $40,000 annual WAC supports meaningful commercial upside if development progresses.

Tenax Therapeutics is burdened by a weak clinical and regulatory profile, as the LEVEL phase III study missed its primary endpoint and key secondary endpoints, with 6MWD showing only a 3.5m treatment difference versus placebo at Week 12 and a p-value of 0.63. The failed Phase 2 HELP premise, coupled with uncertainty over whether the FDA will accept the two-trial path after the miss and the need for statistically significant data that clears a stringent threshold, makes approval materially harder to achieve. Even with IP protection into 2040, the stock faces meaningful downside from trial delays, possible regulatory disagreement, and competitive pressure from sotatercept and relaxin.